Phase 2 Study Results of Novel Investigational Agent for the Treatment of Schizophrenia Announced by Sunovion

A pivotal phase-2 study of a novel psychotropic agent for the treatment of patients with schizophrenia, met its primary endpoints for safety and efficacy.